(VIANEWS) – Impinj (PI), BioMarin Pharmaceutical (BMRN), Radcom Ltd. (RDCM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Impinj (PI)
27.4% sales growth and 16.08% return on equity
Impinj, Inc. operates a cloud connectivity platform in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. Its platform, which comprises multiple product families, wirelessly connects individual items and delivers data about the connected items to business and consumer applications. The company's platform comprises endpoint ICs, a miniature radios-on-a-chip that attaches to a host item and includes a number to identify the item. Its platform also consists of systems products that comprise reader ICs, readers, and gateways to wirelessly provide power to and communicate bidirectionally with endpoint ICs on host items, as well as to read, write, authenticate, and engage the endpoint ICs on those items; and software and algorithms that enables its partners to deliver use cases, such as retail self-checkout and loss prevention, and warehouse pallet and carton tracking to end-users. The company primarily serves retail, supply chain and logistics, aviation, automotive, healthcare, industrial and manufacturing, sports, food, datacenter, travel, banking, and linen and uniform tracking sectors through distributors, system integrators, value-added resellers, and software solution partners. Impinj, Inc. was incorporated in 2000 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Impinj has a trailing twelve months EPS of $0.29.
PE Ratio
Impinj has a trailing twelve months price to earnings ratio of 480.48. Meaning, the purchaser of the share is investing $480.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.08%.
Moving Average
Impinj’s value is way below its 50-day moving average of $159.74 and way higher than its 200-day moving average of $118.08.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.2%, now sitting on 314.98M for the twelve trailing months.
Volume
Today’s last reported volume for Impinj is 626263 which is 36.46% above its average volume of 458932.
2. BioMarin Pharmaceutical (BMRN)
14.1% sales growth and 5.1% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.32.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 67.15. Meaning, the purchaser of the share is investing $67.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1364070 which is 45.5% below its average volume of 2502930.
Sales Growth
BioMarin Pharmaceutical’s sales growth is 15.6% for the current quarter and 14.1% for the next.
Moving Average
BioMarin Pharmaceutical’s value is higher than its 50-day moving average of $83.34 and above its 200-day moving average of $86.73.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $88.64 at 16:22 EST, way under its 52-week high of $99.56 and way higher than its 52-week low of $73.68.
3. Radcom Ltd. (RDCM)
10% sales growth and 5.8% return on equity
RADCOM Ltd. provides 5G ready cloud-native network intelligence and service assurance solutions for telecom operators or communication service providers (CSPs). It offers RADCOM ACE, including RADCOM Service Assurance, a cloud-native, 5G-ready, and virtualized service assurance solutions, which allows telecom operators to gain end-to-end network visibility and customer experience insights across all networks; RADCOM Network Visibility, a cloud-native network packet broker and filtering solution that allows CSPs to manage network traffic at scale across multiple cloud environments, and control the visibility layer to perform analysis of select datasets; and RADCOM Network Insights, a business intelligence solution that offers insights for multiple use cases enabled by data captured and correlated through RADCOM Network Visibility and RADCOM Service Assurance. The company also provides solutions for mobile and fixed networks, such as 5G, long term evolution, voice over LTE, voice over Wifi, IP multimedia subsystem, voice over IP, and universal mobile telecommunication service. It sells its products directly, as well as through a network of distributors and resellers in North America, Asia, Latin America, Europe, the Middle East, and Africa. The company was formerly known as Big Blue Catalogue Ltd. and changed its name to RADCOM Ltd. in 1989. RADCOM Ltd. was incorporated in 1985 and is headquartered in Tel Aviv, Israel.
Earnings Per Share
As for profitability, Radcom Ltd. has a trailing twelve months EPS of $0.31.
PE Ratio
Radcom Ltd. has a trailing twelve months price to earnings ratio of 31.23. Meaning, the purchaser of the share is investing $31.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.8%.
Sales Growth
Radcom Ltd.’s sales growth for the next quarter is 10%.
Volume
Today’s last reported volume for Radcom Ltd. is 22667 which is 5.97% below its average volume of 24108.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.6%, now sitting on 56.13M for the twelve trailing months.
Moving Average
Radcom Ltd.’s value is higher than its 50-day moving average of $9.53 and above its 200-day moving average of $9.25.
4. Primerica (PRI)
5.3% sales growth and 21.42% return on equity
Primerica, Inc., together with its subsidiaries, provides financial products to middle income households in the United States and Canada. The company operates in three segments: Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. It underwrites individual term life insurance products. The company also provides mutual funds and various retirement plans, managed investments, variable and fixed annuities, fixed indexed annuities, and segregated funds. In addition, it offers auto and homeowners' insurance, home automation solutions, and mortgage loans; ID theft defense services; and insurance products, including supplemental medical and dental, accidental death, and disability for small businesses. Further, the company provides prepaid legal services that assist subscribers with legal matters, such as drafting wills, living wills and powers of attorney, trial defense, and motor vehicle-related matters. It distributes and sells its products through licensed sales representatives. Primerica, Inc. was founded in 1927 and is headquartered in Duluth, Georgia.
Earnings Per Share
As for profitability, Primerica has a trailing twelve months EPS of $12.49.
PE Ratio
Primerica has a trailing twelve months price to earnings ratio of 20.37. Meaning, the purchaser of the share is investing $20.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.42%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Aug 21, 2024, the estimated forward annual dividend rate is 3.6 and the estimated forward annual dividend yield is 1.42%.
Volume
Today’s last reported volume for Primerica is 122585 which is 26.48% below its average volume of 166750.
Yearly Top and Bottom Value
Primerica’s stock is valued at $254.41 at 16:22 EST, below its 52-week high of $256.56 and way above its 52-week low of $184.76.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 9.8% and 11.3%, respectively.
Previous days news about Primerica(PRI)
- According to Zacks on Thursday, 15 August, "Other players in the insurance industry are Brighthouse Financial (BHF Quick QuoteBHF – Free Report) , Reinsurance Group of America, Incorporated (RGA Quick QuoteRGA – Free Report) and Primerica (PRI Quick QuotePRI – Free Report) .", "A strong business model makes Primerica well-poised to cater to the middle market’s increased demand for financial security."
